Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway

Esther P. Jane(Children's Hospital of Pittsburgh), Ian F. Pollack(Children's Hospital of Pittsburgh)

Molecular Cancer Therapeutics

January 1, 2011

10.1158/1535-7163.mct-10-0725

Cited by 75

Related Papers

Intertumoral Heterogeneity within Medulloblastoma Subgroups

|Cancer Cell|2017|1.3k

Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma

|Journal of Clinical Oncology|2013|488

Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group

|Journal of Clinical Oncology|2012|433

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

|The Lancet Oncology|2016|369

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group

|Neuro-Oncology|2011|342